Infectious Diseases Collaboration and Licensing Deals 2016-2023
SUMMARY
Infectious Diseases Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023
DESCRIPTION
Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of infectious diseases deals from 2016 to 2023.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of infectious diseases dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in infectious diseases dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the infectious diseases field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in infectious diseases dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of infectious diseases deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of infectious diseases deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in infectious diseases deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key benefits
Infectious Diseases Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse infectious diseases collaboration and licensing deals
Benchmark analysis – identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Report scope
Infectious Diseases Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of infectious diseases trends and structure of deals entered into by leading biopharma companies worldwide.
Infectious Diseases Collaboration and Licensing Deals includes:
Trends in infectious diseases dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of infectious diseases deal records covering pharmaceutical and biotechnology
The leading infectious diseases deals by value
Most active infectious diseases licensing dealmakers
In Infectious Diseases Collaboration and Licensing Deals, the available deals are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Infectious Diseases Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
BENEFITS
Infectious Diseases Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse infectious diseases collaboration and licensing deals
Benchmark analysis – identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Infectious Diseases Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023
DESCRIPTION
Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of infectious diseases deals from 2016 to 2023.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of infectious diseases dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in infectious diseases dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the infectious diseases field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in infectious diseases dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of infectious diseases deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of infectious diseases deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in infectious diseases deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key benefits
Infectious Diseases Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse infectious diseases collaboration and licensing deals
Benchmark analysis – identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Report scope
Infectious Diseases Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of infectious diseases trends and structure of deals entered into by leading biopharma companies worldwide.
Infectious Diseases Collaboration and Licensing Deals includes:
Trends in infectious diseases dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of infectious diseases deal records covering pharmaceutical and biotechnology
The leading infectious diseases deals by value
Most active infectious diseases licensing dealmakers
In Infectious Diseases Collaboration and Licensing Deals, the available deals are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Infectious Diseases Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
BENEFITS
Infectious Diseases Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse infectious diseases collaboration and licensing deals
Benchmark analysis – identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Executive Summary
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN INFECTIOUS DISEASES DEALMAKING
2.1. Introduction
2.2. Infectious diseases partnering over the years
2.3. Infectious diseases partnering by deal type
2.4. Infectious diseases partnering by industry sector
2.5. Infectious diseases partnering by stage of development
2.6. Infectious diseases partnering by technology type
2.7. Infectious diseases partnering by therapeutic indication
CHAPTER 3 – FINANCIAL DEAL TERMS FOR INFECTIOUS DISEASES PARTNERING
3.1. Introduction
3.2. Disclosed financials terms for infectious diseases partnering
3.3. Infectious diseases partnering headline values
3.4. Infectious diseases deal upfront payments
3.5. Infectious diseases deal milestone payments
3.6. Infectious diseases royalty rates
CHAPTER 4 – LEADING INFECTIOUS DISEASES DEALS AND DEALMAKERS
4.1. Introduction
4.2. Most active in infectious diseases partnering
4.3. List of most active dealmakers in infectious diseases
4.4. Top infectious diseases deals by value
CHAPTER 5 – INFECTIOUS DISEASES CONTRACT DOCUMENT DIRECTORY
5.1. Introduction
5.2. Infectious diseases partnering deals where contract document available
CHAPTER 6 – INFECTIOUS DISEASES DEALMAKING BY THERAPEUTIC TARGET
6.1. Introduction
6.2. Deals by infectious diseases therapeutic target
Deal directory
Deal directory – Infectious diseases deals by company A-Z 2016 to 2023
Deal directory – Infectious diseases deals by technology type 2016 to 2023
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Infectious diseases partnering since 2016
Figure 2: Infectious diseases partnering by deal type since 2016
Figure 3: Infectious diseases partnering by industry sector since 2016
Figure 4: Infectious diseases partnering by stage of development since 2016
Figure 5: Infectious diseases partnering by technology type since 2016
Figure 6: Infectious diseases partnering by indication since 2016
Figure 7: Infectious diseases deals with a headline value
Figure 8: Infectious diseases deals with upfront payment values
Figure 9: Infectious diseases deals with milestone payment
Figure 10: Infectious diseases deals with royalty rates
Figure 11: Active infectious diseases dealmaking activity since 2016
Figure 12: Top infectious diseases deals by value since 2016
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN INFECTIOUS DISEASES DEALMAKING
2.1. Introduction
2.2. Infectious diseases partnering over the years
2.3. Infectious diseases partnering by deal type
2.4. Infectious diseases partnering by industry sector
2.5. Infectious diseases partnering by stage of development
2.6. Infectious diseases partnering by technology type
2.7. Infectious diseases partnering by therapeutic indication
CHAPTER 3 – FINANCIAL DEAL TERMS FOR INFECTIOUS DISEASES PARTNERING
3.1. Introduction
3.2. Disclosed financials terms for infectious diseases partnering
3.3. Infectious diseases partnering headline values
3.4. Infectious diseases deal upfront payments
3.5. Infectious diseases deal milestone payments
3.6. Infectious diseases royalty rates
CHAPTER 4 – LEADING INFECTIOUS DISEASES DEALS AND DEALMAKERS
4.1. Introduction
4.2. Most active in infectious diseases partnering
4.3. List of most active dealmakers in infectious diseases
4.4. Top infectious diseases deals by value
CHAPTER 5 – INFECTIOUS DISEASES CONTRACT DOCUMENT DIRECTORY
5.1. Introduction
5.2. Infectious diseases partnering deals where contract document available
CHAPTER 6 – INFECTIOUS DISEASES DEALMAKING BY THERAPEUTIC TARGET
6.1. Introduction
6.2. Deals by infectious diseases therapeutic target
Deal directory
Deal directory – Infectious diseases deals by company A-Z 2016 to 2023
Deal directory – Infectious diseases deals by technology type 2016 to 2023
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Infectious diseases partnering since 2016
Figure 2: Infectious diseases partnering by deal type since 2016
Figure 3: Infectious diseases partnering by industry sector since 2016
Figure 4: Infectious diseases partnering by stage of development since 2016
Figure 5: Infectious diseases partnering by technology type since 2016
Figure 6: Infectious diseases partnering by indication since 2016
Figure 7: Infectious diseases deals with a headline value
Figure 8: Infectious diseases deals with upfront payment values
Figure 9: Infectious diseases deals with milestone payment
Figure 10: Infectious diseases deals with royalty rates
Figure 11: Active infectious diseases dealmaking activity since 2016
Figure 12: Top infectious diseases deals by value since 2016
